Key result
Migalastat therapy linked to 9-year cardiac remodeling in a woman with Fabry disease.
Why the study?
Does migalastat therapy improve long-term cardiac remodeling in a heterozygote woman with Fabry disease?
Does migalastat therapy improve long-term cardiac remodeling in a heterozygote woman with Fabry disease?
This case report describes the 9-year cardiac remodeling outcomes of migalastat therapy in a heterozygous female with Fabry disease.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for migalastat in Fabry cardiomyopathy; larger studies needed before practice change.
Fabry disease (FD) is a rare X‑linked lysosomal disorder in which long‑term cardiac outcomes, particularly in heterozygous females, remain incompl...
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) studied this question. Migalastat therapy was associated with long-term cardiac remodeling over a 9-year period in a heterozygous woman with Fabry disease and the N224S mutation.
Synapse has enriched 10 related papers. Consider them for comparative context: